“Men with early stage prostate cancer who ate a low-fat diet supplemented with fish oil had lower amounts of proinflammation molecules in their blood and lower prostate tumor cell proliferation compared with men who ate a high-fat Western diet. Men on the low-fat fish oil diet had lower serum levels of omega-6 fatty acids and high levels of serum omega-3 fatty acids compared with the prostate cancer patients who consumed a Western diet. The experimental group also had lower levels of the proinflammatory eicosanoid 15(S)-hydroxyeicosatetraenoic acid, or 15(S)-HETE, which has been previously shown to be associated with cancer. The decline in mean 15(S)-HETE was 7.2% in the low-fat diet group compared with 24.7% in the high-fat diet group (P = .02). The men in the low-fat diet group also had a lower cell cycle progression score, a marker for the aggressiveness of a cancer.”
Research from Fred Hutchinson Cancer Research Center has confirmed that high blood levels of omega-3 fatty acids, found in fish oil, increase the risk of aggressive prostate cancer by 71 percent, and increase the overall risk of prostate cancer by 43 percent. The results of the new study involving 2227 men confirm similar findings from a clinical study conducted in 2011, as well as another large European study. Scientists are uncertain why fish oil increases the risk of prostate cancer, but a potential cause is that the omega-3 fatty acids break down into compounds that may damage DNA and lead to cancer development.
In a multicenter randomized phase II trial of gemcitabine (arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C), similar progression-free survival (PFS) and overall survival (OS) were observed in all arms. We performed an exploratory, blinded, retrospective analysis of plasma or serum samples collected as part of the trial to investigate the ability of VeriStrat (VS) to predict treatment outcomes.
Gemcitabine is the superior treatment for elderly patients with VS Poor status. First-line erlotinib for elderly patients with VS Good status may warrant further investigation.
Although both erlotinib and gefitinib target the epidermal growth factor receptor (EGFR), erlotinib is effective in patients with EGFR wild-type or mutated tumors, whereas gefitinib is only beneficial for patients with activating mutations. To determine whether these differences in clinical outcomes can be attributed to their respective protein interaction profiles, a label-free, quantitative chemical proteomics study was performed. We propose that, in an EGFR wild-type context, erlotinib may have a complementary mode of action by inhibiting integrin-linked kinase (ILK), -parvin and PINCH (IPP) complex activities, resulting in the slowing down of the metastatic process of epithelial tumors.
Altered expression of MUC4 plays an oncogenic role in various cancers, including pancreatic, ovarian, and breast. This study evaluates the expression and role of MUC4 in non-small-cell lung cancer (NSCLC).
MUC4 plays a tumor-suppressor role in NSCLC by altering p53 expression in NSCLC. Decrease in MUC4 expression in advanced tumor stages also seems to confirm the novel protective function of MUC4 in NSCLC.
CollabRx, Inc. announced the release of a new version of its Therapy Finder™application (“app”) for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient’s tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company’s website and via distribution partners such as MedPage Today, Everyday Health’s physician portal.
The objective of this research was to identify impact of risk factors on changing trends of lung cancer in a case control study. In the study conducted from 2006 to 2010 the cases included newly diagnosed patients of histological proven lung carcinoma attending the radiotherapy department. Change in trend was observed in patients diagnosed at younger age of 57.48 ± 0.56 years in 2010 with adenocarcinoma unlike 62.89 ± 1.21 years in 2006. Females show increase in incidence of lung cancer in 2010. The “active” smokers and years of smoking were significantly high among cases. The incidence of squamous cell carcinoma declined from 47.4% in 2006 to 15% in 2010 whereas adenocarcinoma increased.
Oncolytics Biotech Inc said a mid-stage trial of its experimental lung cancer drug showed that 95 percent of the patients experienced a reduction in the size of their tumors. The drug, Reolysin, was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. It was tested on patients suffering from metastatic or recurrent squamous cell carcinoma of the lung.
RNA-dependent protein kinase (PKR) is an independent prognostic variable in patients with non-small-cell lung cancer (NSCLC). In the current study, we investigated the correlation between PKR and 25 other biomarkers for NSCLC, identified the markers that could further improve the prognostic significance of PKR and elucidated the mechanisms of interaction between these markers and PKR.
PKR/EphA2 is a significant predictor of prognosis for NSCLC. PKR/EphA2 may be a promising approach to improving screening efficiency and predicting prognosis in patients with NSCLC.